Ken Griffin Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $23.8 Million - $29.2 Million	-101,700 Reduced 39.84%	153,600 $42.3 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $243,627 - $419,900	-1,700 Reduced 0.66%	255,300 $62 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $16.2 Million - $21.9 Million	110,400 Added 75.31%	257,000 $38.4 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $5.62 Million - $7.29 Million	37,100 Added 33.88%	146,600 $28.1 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $2.83 Million - $3.51 Million	16,600 Added 17.87%	109,500 $19.4 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $3.42 Million - $3.92 Million	-18,500 Reduced 16.61%	92,900 $17.6 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $10.9 Million - $14 Million	-59,600 Reduced 34.85%	111,400 $22.3 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $1.6 Million - $2.08 Million	-8,600 Reduced 4.79%	171,000 $40.6 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $24.8 Million - $41.6 Million	-179,100 Reduced 49.93%	179,600 $35.9 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.